Filing Flows › Angiodynamics (ANGO) › Q4 FY26 › vs Q4 FY25
Angiodynamics (ANGO) Q4 FY26 vs Q4 FY25 (year over year)
Angiodynamics's revenue rose $6.4M (+8%) from $80.2M in Q4 FY25 to $86.6M in Q4 FY26.
Angiodynamics, Q4 FY26: revenue $86.6M (+8% year over year), operating margin -11.8%, net loss $11.4M, operating cash flow $17.5M. The chart draws each line against Q4 FY25, the increases inside each band.
Margins
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Free cash flow margin | 19.7% | 22.5% | -2.8 pts |
Every line
| Line | Q4 FY26 | Q4 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $86.6M | $80.2M | $6.4M | +8% |
| Net loss | $11.4M | $6.0M | $5.4M | +89% |
| Costs & expenses | $98.0M | $86.3M | $11.7M | +14% |
| Operating costs | $96.8M | $85.9M | $10.9M | +13% |
| Interest & other, net | $840K | $322K | $518K | +161% |
| Income tax | $370K | −$60K | $430K | — |
| Cost of revenue | $39.8M | $37.9M | $1.9M | +5% |
| Research & development | $8.2M | $6.6M | $1.6M | +24% |
| Sales & marketing | $31.1M | $26.4M | $4.7M | +18% |
| General & admin | $10.3M | $10.2M | $30K | +0.3% |
| Other operating costs | $7.4M | $4.7M | $2.7M | +56% |
| Operating cash sources | $28.9M | $24.9M | $4.0M | +16% |
| Depreciation & amortization | $5.6M | $5.8M | −$236K | -4% |
| Share-based compensation | $3.9M | $1.6M | $2.3M | +139% |
| Working capital & other | $19.3M | $17.4M | $2.0M | +11% |
| Net loss absorbed | $11.4M | $6.0M | $5.4M | +89% |
| Operating cash flow | $17.5M | $18.8M | −$1.4M | -7% |
| Free cash flow (OCF − capex) | $17.0M | $18.0M | −$995K | -6% |
| Capital expenditures | $413K | $777K | −$364K | -47% |
Questions
How much did Angiodynamics's revenue grow year over year in Q4 FY26?
Angiodynamics's revenue rose $6.4M (+8%) from $80.2M in Q4 FY25 to $86.6M in Q4 FY26.